German healthcare conglomerate Fresenius (FREG.DE) raised the full-year profit outlook for its generic infusion drug unit Kabi for the third time this year as it benefits from rivals’ supply shortages longer than previously thought. The division now expects organic sales growth of about 9 percent and a margin of earnings before interest and tax (EBIT) over sales of about 20.5 percent, which is the upper end of its previous target range, Fresenius said on Wednesday. Previously, it had projected organic sales growth of 7-9 percent and an EBIT margin of 20-20.5 percent.
